Search
News & Events
Telethon donations fund early flu protection for bubsBabies worldwide could have access to life-saving influenza vaccinations from just eight weeks of age thanks to researchers at The Kids Research Institute Australia and the generous support of the Telethon community.
News & Events
Study finds Covid-19 severity reduced for childrenAn international study examining Covid-19 severity on hospitalised children and adolescents has found that as the virus became more infectious, intensive care admissions dropped across multiple age groups regardless of vaccination status.
News & Events
National guideline to tackle record rates of skin infectionResearchers have developed the first National Healthy Skin Guideline to address record rates of skin infections in Australia’s Indigenous communities.
News & Events
Co-ordinated approach urgently required to slow progression of antibiotic resistanceAboriginal mum and child
News & Events
Outstanding mentor named Eureka prize finalistLeading infectious diseases researcher, Clinical Associate Professor Deborah Lehmann AO, has been named a finalist for the Australian Museum Eureka Prizes for her work training and mentoring a new generation of researchers.
News & Events
Pneumococcal vaccine sees hospital admissions for deadly pneumonia slashed by halfThousands of children born in Papua New Guinea (PNG) no longer face a future cut short by severe pneumonia, thanks to the introduction of pneumococcal vaccination as part of the country’s National Immunisation Program.
Research
The STAMP RSV ProgramSTAMP RSV is a multifaceted program of work with the single focus to prepare the community for the uptake of new and emerging RSV immunisation strategies by providing the evidence to inform public health policy.
Research
Australian Group on Antimicrobial Resistance surveillance outcome programs - bloodstream infections and antimicrobial resistance patterns in Australian children and adolescents 2022 - 2023Between January 2022 and December 2023, there were 1,827 bloodstream infection (BSI) isolates in 1,745 children and adolescents reported to the Australian Group on Antimicrobial Resistance (AGAR) surveillance outcome programs, with 40% of episodes in children aged < 12 months.
Research
Predicting regional and temporal incidence of RSV and influenza hospitalizations in a birth cohort of young Australian childrenWestern Australia experiences multiple climatic zones, influencing the epidemiology of respiratory viruses. We aimed to estimate the true incidence of respiratory syncytial virus and influenza hospitalizations across these different climatic regions using predictive modelling.
Research
Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024Respiratory Syncytial Virus (RSV) causes a significant burden of illness for children under 2 years of age. Nirsevimab, a long-acting monoclonal antibody, was registered for RSV prevention in Australia in 2023. In April 2024, Western Australia (WA) launched the country's first state-wide nirsevimab program for all infants and high-risk children entering their second RSV season.